MAPK3 and fragile X syndrome: Further, a phase I clinical trial of the Ras-ERK1/2 inhibitor, lovastatin, conducted by Dr. Francois Corbin's group showed significant behavioral improvements in FXS patients (Çaku et al., 2014).